Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Q3 revenue up 27.6% to $290.8 million; Cortrophin Gel guidance cut

Mixed Impact 4 of 5 earnings

ANI Pharmaceuticals reported third quarter 2026 net revenues of $290.8 million, up 27.6%, and GAAP diluted earnings per share of $1.51 versus $1.13 a year earlier. It cut its 2026 Cortrophin Gel revenue guidance to $480 million to $500 million from $520 million to $540 million, citing slower-than-expected conversion of demand into patients, while raising its adjusted EBITDA and adjusted EPS guidance, and it announced a recommended offer to acquire Egetis Therapeutics.

Key points

  • Q3 2026 Cortrophin Gel net revenues were $138.7 million, up 36.1%, while Brands revenue fell 6.5% to $10.0 million.
  • 2026 Cortrophin Gel revenue guidance was revised to $480 million to $500 million, down from $520 million to $540 million; total company revenue guidance was narrowed to $1,085 million to $1,125 million.
  • Adjusted non-GAAP EBITDA guidance was raised to $290 million to $300 million, and adjusted non-GAAP diluted EPS guidance was raised to $9.37 to $9.71.
  • The Egetis offer is SEK 11.25 per share, valued at approximately $560 million including incentive programs; the acceptance period is expected to run from about November 20, 2026 to December 18, 2026.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:56 AM ET
Accession number0001023024-26-000077

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.